Delivery Order HHSN261201200020I-HHSN26100006
Award Date
8/26/14
Potential Completion Date
8/25/17
Potential Value
$474K
Federal Agency
National Cancer Institute
Awardee
University Of Oklahoma
Ultimate Awardee
University Of Oklahoma
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...
This is a firm fixed price delivery order awarded by the National Cancer Institute (NCI), a civilian federal agency, to the University of Oklahoma Health Sciences Center (OU HCSC) division of the University of Oklahoma. The $598,566.75 award is under the NCI's "PREVENT Cancer Program (PREVENT)" and aims to optimize Genomic Evidence Multiscale (GEM) models for predicting the progression of high-risk pancreatic lesions to pancreatic ductal adenocarcinoma (PDAC). The contract has a period...
This is a firm-fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Oklahoma (OU) under the PREVENT Preclinical Drug Development Program master IDIQ contract. The contract is for the "FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA" project, with a ceiling value of $1,029,991.00 and a period of performance through September 14, 2025. The contract has no set-aside designation. As a public research...
This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The contract is part of the Preclinical Agent Development Assays 2012-2016 indefinite delivery, indefinite quantity (IDIQ) vehicle. It is for "OTHER FUNCTIONS - IN VITRO AND IN VIVO AGENT DEVELOPMENT ASSAYS" services with a ceiling value of $1,899.49....
This is a firm fixed price Delivery Order awarded by the National Cancer Institute (NCI) to the University of Oklahoma (OU) for the "Prevention of Colorectal Cancer by ONC201" project. The contract, which is part of the NCI's "PREVENT Cancer Program", has a period of performance from September 2016 to September 2018 and a ceiling value of $221,345. The work is focused on preclinical cancer prevention research, specifically evaluating the efficacy of the drug ONC201 for...
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma Health Sciences Center Division. The contract is part of the NCI's "PREVENT Cancer Program (PREVENT)" and covers a "CONTRACT ORIENTATION AND KICK-OFF MEETING" with a period of performance from September 22, 2015 to December 31, 2015. The contract has a ceiling value of $4,217.44 and is a Delivery Order...
The federal contract award with ID HHSN261200533000C was issued by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The contract, valued at $19,658,911.55, is for preclinical efficacy and intermediate endpoint assays. It is a definitive, cost-no-fee contract without a set-aside designation. The University of Oklahoma, as the prime contractor, will provide a range...
This federal contract award, valued at $598,079.38, was issued by the National Cancer Institute (NCI) to the University of Oklahoma (OU) Health Sciences Center Division. The contract supports the "COMBINATION OF ASPIRIN OR NAPROXEN WITH OMERPRAZOLE FOR COLORECTAL CANCER CHEMOPREVENTION WITH CLINICALLY RELEVANT DOSES" effort under the NCI's Preclinical Prevent Cancer Program. The contract is a delivery order placed against the NCI's broader "PREVENT Cancer Program (PREVENT)"...
This is a $521,214.97 Firm Fixed Price delivery order awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Oklahoma Health Sciences Center to conduct research on the chemoprevention of colorectal cancer with olmesartan medoxomil. The order is part of the NIH's PREVENT Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers for cancer prevention. The delivery order does not have a set-aside designation. University...